Simultaneous quantification of tiotropium bromide impurities G + H in capsule formulation by LC-MS/MS

Erkol S., Güleli M., Çalışkan C., KOCAOBA S.

European Journal of Mass Spectrometry, vol.30, no.1, pp.76-83, 2024 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 30 Issue: 1
  • Publication Date: 2024
  • Doi Number: 10.1177/14690667231217879
  • Journal Name: European Journal of Mass Spectrometry
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, Compendex, EMBASE, INSPEC, MEDLINE
  • Page Numbers: pp.76-83
  • Keywords: impurity G, impurity H, LC-MS/MS, LC-Q/TOF, method validation, Tiotropium bromide
  • Yıldız Technical University Affiliated: Yes


Tiotropium Bromide is a long-acting bronchodilator that is used in the treatment of chronic obstructive pulmonary disease (COPD) and asthma bronchodilator or bronchiolitis, which are substances that expand the bronchi and reduce resistance in the respiratory tract and increase airflow to the lungs. For Tiotropium Bromide found in inhaler capsules to treat COPD, determining the relevant impurities G and H, which are not UV active, is crucial. For this purpose, a new and sensitive liquid chromatography triple-quadrupole mass spectrometry (LC-MS/MS) detection with electrospray ionization by using multiple reaction monitoring in the positive mode method was developed and validated. The identity of the compounds was supported by using LC-Q/TOF. All chromatographic studies were performed with a Zorbax Eclipse XDB-C8 (150 mm x 4.6 mm, 5.0 µm) column with a total injection time of 13 min at a flow rate of 0.4 ml/min as a gradient. The limit of detection (LOD) and limit of quantitation (LOQ) in the current study range were determined as 1.0 ppb and 2.5 ppb, respectively. The results of the validation parameters following the ICH Q2(R1) guideline were determined within the acceptance criteria.